MHUA
Meihua International Medical Technologies Co., Ltd.
Medical - Instruments & Supplies
Market Cap$2M
5Y Perf.-99.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MHUA vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-83.3%
MHUA vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MHUA | NVCR |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $2M | $1.92B |
| Revenue (TTM) | $184M | $674M |
| Net Income (TTM) | $19M | $-173M |
| Gross Margin | 33.6% | 75.2% |
| Operating Margin | 12.6% | -27.2% |
| Forward P/E | 0.2x | — |
| Total Debt | $8M | $290M |
| Cash & Equiv. | $16M | $103M |
MHUA vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MHUA
NVCR
| Stock | Feb 22 | Apr 26 | Return |
|---|---|---|---|
| Meihua Internationa… (MHUA) | 100 | 0.9 | -99.1% |
| NovoCure Limited (NVCR) | 100 | 16.7 | -83.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MHUA vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NVCR leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Meihua International Medical Technologies Co., Ltd. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
MHUA
Meihua International Medical Technologies Co., Ltd.
The Defensive Pick
MHUA is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 2.86, Low D/E 5.0%, current ratio 5.26x
- 10.1% margin vs NVCR's -25.7%
- 9.7% ROA vs NVCR's -16.5%, ROIC 7.4% vs -16.4%
Best for: sleep-well-at-night
NVCR
NovoCure Limited
The Income Pick
NVCR carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 2.20
- Rev growth 8.3%, EPS growth 21.8%, 3Y rev CAGR 6.8%
- 30.3% 10Y total return vs MHUA's -99.4%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NVCR | 8.3% revenue growth vs MHUA's -0.2% |
| Quality / Margins | MHUA | 10.1% margin vs NVCR's -25.7% |
| Stability / Safety | NVCR | Beta 2.20 vs MHUA's 2.86 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NVCR | +1.1% vs MHUA's -73.6% |
| Efficiency (ROA) | MHUA | 9.7% ROA vs NVCR's -16.5%, ROIC 7.4% vs -16.4% |
MHUA vs NVCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMHUALAGGINGNVCR
NVCRNovoCure Limited
2leads
MHUAMeihua International …
3leads
6 Total Categories
CATEGORYLEADERvs NVCRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
MHUA4/6
Valuation MetricsMultiples, price ratios, and targets
MHUA2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MHUA8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NVCR5/6
Risk & VolatilityBeta, volatility, and downside exposure
NVCR2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
MHUA leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 3.7x MHUA's $184M. MHUA is the more profitable business, keeping 10.1% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, NVCR holds the edge at +12.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MHUAMeihua Internatio… | NVCRNovoCure Limited |
|---|---|---|
| RevenueTrailing 12 months | $184M | $674M |
| EBITDAEarnings before interest/tax | $24M | -$165M |
| Net IncomeAfter-tax profit | $19M | -$173M |
| Free Cash FlowCash after capex | $12M | -$48M |
| Gross MarginGross profit ÷ Revenue | +33.6% | +75.2% |
| Operating MarginEBIT ÷ Revenue | +12.6% | -27.2% |
| Net MarginNet income ÷ Revenue | +10.1% | -25.7% |
| FCF MarginFCF ÷ Revenue | +6.6% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -16.2% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -35.8% | -100.0% |
MHUA leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
MHUA leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | MHUAMeihua Internatio… | NVCRNovoCure Limited |
|---|---|---|
| Market CapShares × price | $2M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | -$6M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | 0.19x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | -0.40x | — |
| Price / SalesMarket cap ÷ Revenue | 0.02x | 2.92x |
| Price / BookPrice ÷ Book value/share | 0.01x | 5.51x |
| Price / FCFMarket cap ÷ FCF | 0.14x | — |
MHUA leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
MHUA leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
MHUA delivers a 11.2% return on equity — every $100 of shareholder capital generates $11 in annual profit, vs $-51 for NVCR. MHUA carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), NVCR scores 5/9 vs MHUA's 4/9, reflecting solid financial health.
| Metric | MHUAMeihua Internatio… | NVCRNovoCure Limited |
|---|---|---|
| ROE (TTM)Return on equity | +11.2% | -50.8% |
| ROA (TTM)Return on assets | +9.7% | -16.5% |
| ROICReturn on invested capital | +7.4% | -16.4% |
| ROCEReturn on capital employed | +9.4% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.05x | 0.85x |
| Net DebtTotal debt minus cash | -$8M | $187M |
| Cash & Equiv.Liquid assets | $16M | $103M |
| Total DebtShort + long-term debt | $8M | $290M |
| Interest CoverageEBIT ÷ Interest expense | 31.87x | -96.80x |
MHUA leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NVCR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NVCR five years ago would be worth $875 today (with dividends reinvested), compared to $59 for MHUA. Over the past 12 months, NVCR leads with a +1.1% total return vs MHUA's -73.6%. The 3-year compound annual growth rate (CAGR) favors NVCR at -37.6% vs MHUA's -71.3% — a key indicator of consistent wealth creation.
| Metric | MHUAMeihua Internatio… | NVCRNovoCure Limited |
|---|---|---|
| YTD ReturnYear-to-date | +271.2% | +28.3% |
| 1-Year ReturnPast 12 months | -73.6% | +1.1% |
| 3-Year ReturnCumulative with dividends | -97.6% | -75.7% |
| 5-Year ReturnCumulative with dividends | -99.4% | -91.3% |
| 10-Year ReturnCumulative with dividends | -99.4% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -71.3% | -37.6% |
NVCR leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
NVCR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NVCR is the less volatile stock with a 2.20 beta — it tends to amplify market swings less than MHUA's 2.86 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs MHUA's 11.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MHUAMeihua Internatio… | NVCRNovoCure Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.86x | 2.20x |
| 52-Week HighHighest price in past year | $64.00 | $20.06 |
| 52-Week LowLowest price in past year | $2.05 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +11.9% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 49.3 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 1K | 1.5M |
NVCR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | MHUAMeihua Internatio… | NVCRNovoCure Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $33.50 |
| # AnalystsCovering analysts | — | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +9.6% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MHUA leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). NVCR leads in 2 (Total Returns, Risk & Volatility).
Best OverallMeihua International Medica… (MHUA)Leads 3 of 6 categories
Loading custom metrics...
MHUA vs NVCR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MHUA or NVCR a better buy right now?
For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.
3% revenue growth year-over-year, versus -0. 2% for Meihua International Medical Technologies Co. , Ltd. (MHUA). Meihua International Medical Technologies Co. , Ltd. (MHUA) offers the better valuation at 0. 2x trailing P/E, making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MHUA or NVCR?
Over the past 5 years, NovoCure Limited (NVCR) delivered a total return of -91.
3%, compared to -99. 4% for Meihua International Medical Technologies Co. , Ltd. (MHUA). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus MHUA's -99. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MHUA or NVCR?
By beta (market sensitivity over 5 years), NovoCure Limited (NVCR) is the lower-risk stock at 2.
20β versus Meihua International Medical Technologies Co. , Ltd. 's 2. 86β — meaning MHUA is approximately 30% more volatile than NVCR relative to the S&P 500. On balance sheet safety, Meihua International Medical Technologies Co. , Ltd. (MHUA) carries a lower debt/equity ratio of 5% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
04Which is growing faster — MHUA or NVCR?
By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.
3% versus -0. 2% for Meihua International Medical Technologies Co. , Ltd. (MHUA). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -18. 4% for Meihua International Medical Technologies Co. , Ltd.. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MHUA or NVCR?
Meihua International Medical Technologies Co.
, Ltd. (MHUA) is the more profitable company, earning 11. 2% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 11. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MHUA leads at 14. 8% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MHUA or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MHUA or NVCR better for a retirement portfolio?
For long-horizon retirement investors, NovoCure Limited (NVCR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
Meihua International Medical Technologies Co. , Ltd. (MHUA) carries a higher beta of 2. 86 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVCR: +30. 3%, MHUA: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MHUA and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MHUA is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(MHUA: -16.2% · NVCR: 12.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.